Literature DB >> 17909312

Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient.

Beth E Crowner1, Janice E Brunstrom, Brad A Racette.   

Abstract

Botulinum toxin A is commonly used to reduce spasticity and dystonia in children with cerebral palsy. We report a pediatric patient who developed systemic botulism as a result of a severe overdose of the injected toxin (40 U/kg). This case highlights the importance of physicians having adequate knowledge of primate and human literature on the lethal dose, 50% of botulinum toxin A before injecting children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909312     DOI: 10.1097/WNF.0b013e31804b1a0d

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  14 in total

1.  Substrates and controls for the quantitative detection of active botulinum neurotoxin in protease-containing samples.

Authors:  Karine Bagramyan; Bruce E Kaplan; Luisa W Cheng; Jasmin Strotmeier; Andreas Rummel; Markus Kalkum
Journal:  Anal Chem       Date:  2013-05-22       Impact factor: 6.986

Review 2.  Botulinum Toxin as a Treatment for Refractory Gastroparesis: a Literature Review.

Authors:  Ashley Thomas; Bruno de Souza Ribeiro; Miguel Malespin; Silvio W de Melo
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

3.  Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study.

Authors:  Leonel Rodriguez; Rachel Rosen; Michael Manfredi; Samuel Nurko
Journal:  Gastrointest Endosc       Date:  2012-02       Impact factor: 9.427

4.  Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Authors:  Alan R Jacobson; Michael Adler; Nicholas R Silvaggi; Karen N Allen; Genessa M Smith; Ross A Fredenburg; Ross L Stein; Jong-Beak Park; Xiaochuan Feng; Charles B Shoemaker; Sharad S Deshpande; Michael C Goodnough; Carl J Malizio; Eric A Johnson; Sabine Pellett; William H Tepp; Saul Tzipori
Journal:  Toxicon       Date:  2017-07-08       Impact factor: 3.033

5.  Small molecules showing significant protection of mice against botulinum neurotoxin serotype A.

Authors:  Yuan-Ping Pang; Jon Davis; Shaohua Wang; Jewn Giew Park; Madhusoodana P Nambiar; James J Schmidt; Charles B Millard
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 6.  Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE).

Authors:  Brian J Hoare; Margaret A Wallen; Christine Imms; Elmer Villanueva; Hyam Barry Rawicki; Leeanne Carey
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

7.  [Botulinum toxin A in children with infantile cerebral palsy: indications and treatment concepts].

Authors:  R Placzek
Journal:  Orthopade       Date:  2010-01       Impact factor: 1.087

Review 8.  Development of treatment concepts for the use of botulinum toxin a in children with cerebral palsy.

Authors:  Richard Placzek; Dagmar Siebold; Julia F Funk
Journal:  Toxins (Basel)       Date:  2010-08-27       Impact factor: 4.546

9.  Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design.

Authors:  Yuan-Ping Pang; Anuradha Vummenthala; Rajesh K Mishra; Jewn Giew Park; Shaohua Wang; Jon Davis; Charles B Millard; James J Schmidt
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

10.  Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice.

Authors:  Padma Singh; Manglesh Kumar Singh; Dilip Chaudhary; Vinita Chauhan; Pranay Bharadwaj; Apurva Pandey; Nisha Upadhyay; Ram Kumar Dhaked
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.